Patents by Inventor Jagath R. Junutula

Jagath R. Junutula has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
    Publication number: 20100260748
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: March 31, 2010
    Publication date: October 14, 2010
    Inventors: Kristi Elkins, Andrew Polson, Allen Ebens, Camelia Adams, Bing Zheng, Jagath R. Junutula, Jo-Anne Hongo, Yan Wu
  • Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
    Patent number: 7723485
    Abstract: Cysteine engineered anti-MUC16 antibodies are engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-MUC16 antibodies are provided. Cysteine engineered anti-MUC16 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-MUC16 antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: May 25, 2010
    Assignee: Genentech, Inc.
    Inventors: Jagath R. Junutula, William Mallet
  • ZIRCONIUM-RADIOLABELED, CYSTEINE ENGINEERED ANTIBODY CONJUGATES
    Publication number: 20100111856
    Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab) are conjugated with one or more zirconium complex (Z) labels through a linker (L) to form cysteine engineered zirconium-labeled antibody conjugates having Formula I: Ab-(L-Z)p??I where p is 1 to 4. Imaging methods and diagnostic uses for zirconium-radiolabeled, cysteine engineered antibody conjugate compositions are disclosed.
    Type: Application
    Filed: November 5, 2009
    Publication date: May 6, 2010
    Inventors: Herman Gill, Jagath R. Junutula, Henry B. Lowman, Jan Marik, Jeff Tinianow, Simon Williams
  • CYSTEINE ENGINEERED ANTI-MUC16 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20080311134
    Abstract: Cysteine engineered anti-MUC16 antibodies are engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-MUC16 antibodies are provided. Cysteine engineered anti-MUC16 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-MUC16 antibody-drug conjugates having Formula I: Ab-(L-D)p ??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Application
    Filed: May 7, 2008
    Publication date: December 18, 2008
    Inventors: Jagath R. Junutula, William Mallet